Artivion (AORT) Income from Continuing Operations (2010 - 2026)
Artivion's (AORT) quarterly Income from Continuing Operations came in at -$13.5 million in Q2 2026, down 1104.46% on a YoY basis from $1.3 million in Q2 2025, and down 1053.42% quarter-over-quarter from $1.4 million in Q1 2026.
Powered by 
Analysis
Artivion (AORT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Artivion (AORT) has reported Income from Continuing Operations for 17 consecutive years, with -$13.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Continuing Operations fell 1104.46% year-over-year to -$13.5 million; the trailing twelve-month figure through Jun 2026 stood at -$3.2 million (up 82.35% YoY), and the FY2025 full-year result was $9.8 million, up 173.12% from the prior year.
- Income from Continuing Operations retreated to -$13.5 million in Q2 2026 per AORT's latest filing, from $1.4 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at $7.5 million in Q1 2024 and bottomed at -$16.5 million in Q4 2024.
- Historically, Income from Continuing Operations has averaged -$3.6 million across 5 years, with a median of -$2.8 million in 2023.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations jumped 384.18% in 2025, then tumbled 1104.46% in 2026.
- Over 5 years, Income from Continuing Operations stood at $2.2 million in 2022, then slumped by 283.26% to -$4.0 million in 2023, then slumped by 314.67% to -$16.5 million in 2024, then jumped by 114.72% to $2.4 million in 2025, then sank by 656.88% to -$13.5 million in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered -$13.5 million, $1.4 million, and $2.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.57 Bn | 178.97 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 124.13 Bn | 118.91 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 118.29 Bn | 109.47 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 104.60 Bn | 101.12 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 66.50 Bn | 65.97 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 49.72 Bn | 45.46 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.97 Bn | 32.51 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 32.23 Bn | 30.29 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.16 Bn | 20.68 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Artivion | 1.23 Bn | 1.16 Bn | 80.52 Mn | -13.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.51 Mn |
| Mar 31, 2026 | 1.42 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Sep 30, 2025 | 6.50 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | -505,000.00 |
| Dec 31, 2024 | -16.48 Mn |
| Sep 30, 2024 | -2.29 Mn |
| Jun 30, 2024 | -2.12 Mn |
| Mar 31, 2024 | 7.53 Mn |
| Dec 31, 2023 | -3.98 Mn |
| Sep 30, 2023 | -9.80 Mn |
| Jun 30, 2023 | -3.38 Mn |
| Mar 31, 2023 | -13.53 Mn |
| Dec 31, 2022 | 2.17 Mn |
| Sep 30, 2022 | -13.71 Mn |
| Jun 30, 2022 | -4.26 Mn |
| Mar 31, 2022 | -3.39 Mn |
| Dec 31, 2021 | -20.10 Mn |
| Sep 30, 2021 | 10.58 Mn |